<DOC>
	<DOCNO>NCT00091143</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , work different way stop tumor cell divide stop grow die . Vaccines make peptide may make body build immune response kill tumor cell . Infusions person 's white blood cell may able replace immune cell destroy chemotherapy . Combining fludarabine vaccine therapy white blood cell infusion may kill tumor cell . PURPOSE : This randomized phase I trial study side effect give vaccine therapy together fludarabine white blood cell infusion see well work treat patient unresectable metastatic melanoma .</brief_summary>
	<brief_title>Fludarabine Followed Vaccine Therapy White Blood Cell Infusions Treating Patients With Unresectable Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity immune effect vaccination comprise modify gp100 peptide ( gp100:209-217 [ 210M ] ) , Montanide ISA-51 , keyhole limpet hemocyanin follow peripheral blood mononuclear cell reinfusion treatment-induced lymphopenia fludarabine patient unresectable metastatic melanoma . - Determine induction antigen-specific T-cell response patient treat regimen . - Determine kinetics duration immune response patient treat regimen . - Compare immunologic effect regimen patient historical result . Secondary - Compare 2 different dose schedule fludarabine , term induction lymphopenia granulocytopenia induction specific immune response vaccine , patient . OUTLINE : This pilot , randomize study . Patients randomize 1 2 treatment arm . Within 2 week start fludarabine , patient undergo leukapheresis 4-6 hour collection peripheral blood mononuclear cell ( PBMCs ) . - Arm I : Patients receive fludarabine IV 30 minute day 1-5 . - Arm II : Patients receive fludarabine arm I day 1 , 3 , 5 . In arm , patient receive autologous PBMCs IV approximately 30 minute day 8 vaccination comprise gp100:209-217 ( 210M ) peptide , Montanide ISA-51 , keyhole limpet hemocyanin subcutaneously day 8 , 22 , 36 , 50 , 64 . Patients stable respond disease continue receive vaccination day 78 every 28-31 day 1 year . Patients follow every 3 month . PROJECTED ACCRUAL : A total 20 patient ( 10 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant melanoma Metastatic unresectable disease Measurable disease HLAA2 positive Received least 1 prior immunotherapy and/or chemotherapy regimen metastatic disease ( first 6 patient ) No know brain metastasis unless previously treat radiotherapy and/or surgery AND stable least 1 month treatment PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Absolute lymphocyte count ≥ 500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL ( transfusion allow ) Hematocrit ≥ 24 % No active bleeding Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) ( unless due Gilbert 's disease ) AST ALT &lt; 3 time ULN Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine &lt; 2 mg/dL No uncontrolled hypercalcemia Cardiovascular No uncontrolled symptomatic congestive heart failure No unstable angina pectoris No uncontrolled cardiac arrhythmia No uncontrolled hypertension Pulmonary No uncontrolled bronchospasm No hemoptysis Immunologic Negative serology follow : HIV1 HIV2 HTLV1 2 Syphilis Rheumatoid factor &lt; 43 units/μL Antinuclear antibody &lt; 11 units/μL No history multiple sclerosis , systemic lupus erythematosus , myasthenia gravis No primary secondary immunodeficiency No active infection No allergy seafood shellfish would preclude study participation Other No active gastrointestinal bleeding No uncontrolled hyperglycemia No medical psychiatric condition social situation would preclude study compliance No uncontrolled illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 34 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior immunization gp100:209217 ( 210M ) peptide Chemotherapy See Disease Characteristics More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy More 2 week since prior steroid therapy except replacement steroid inhale steroid No concurrent corticosteroid except replacement steroid No concurrent dexamethasone Radiotherapy See Disease Characteristics More 2 week since prior radiotherapy Surgery See Disease Characteristics Recovered prior surgery Other No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>